Skip to content
Contact Us
Technology
Clinical Programs
MBRC-101
MBRC-201
Discovery Platform
Pipeline
About Us
News
Technology
Clinical Programs
MBRC-101
MBRC-201
Discovery Platform
Pipeline
About Us
News
Award-Winning Innovation: MBrace was shortlisted "Best New Drug Developer" and awarded "Most Promising Clinical Candidate for MBRC-101" at the 11th Annual World ADC Awards
Technology
Clinical Programs
MBRC-101
MBRC-201
Discovery Platform
Pipeline
About Us
News
Contact Us
Technology
Clinical Programs
MBRC-101
MBRC-201
Discovery Platform
Pipeline
About Us
News
Contact Us
Back
Press Releases
TPS3161: A Multi-center, Open-Label Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors
June 1, 2024
More news
Read the
Press Releases
→
MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting
Read the
Press Releases
→
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
More news
Read the
Press Releases
→
MBrace Therapeutics Presents Trial in Progress Poster for Lead Antibody-Drug Conjugate Program at 2024 ASCO Annual Meeting
Read the
Press Releases
→
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors
For more information about MBrace’s products or programs please contact us at:
info@mbracetrx.com
